Clinical trials: Malignant Tumor With Metastasis
Solid Tumor
Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China
The primary objective is to evaluate the safety and, tolerabilitytolerance, pharmacokinetices and immunogenicity of escalating single doses and subsequent multiple dose of Gentuximab Injection in patients with late recurrence of…
- Trial name
- NCT03313219
- Testing
- Gentuximab Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00372736
- Testing
- AEG35156, docetaxel, protein expression analysis
- Where
- 3 sites in Canada
- Volunteers
- 27 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer, Solid Tumor
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Trial name
- NCT06503783
- Testing
- BL-M17D1
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
- Trial name
- NCT05438329
- Testing
- DB-1305/BNT325, Pembrolizumab, BNT327
- Where
- 93 sites in United States, China and 1 more
- Volunteers
- 1,123 people
- Sponsor
- DualityBio Inc.
Gastrointestinal Stromal Tumors
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
In patients who are receiving nilotinib, nilotinib plasma levels will be measured after 1 month of nilotinib treatment. The relationship between surgery type and nilotinib pharmakokinetic properties will be investigated in this…
- Trial name
- NCT00976612
- Testing
- Nilotinib
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Asan Medical Center
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
This is a Phase 1a/1b, multicenter, open-label, first-in-human (FIH) study with MX006 treatment in patients with selected tumor types known to express B7-H3.
- Trial name
- NCT07807241
- Testing
- MX006
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 120 people
- Sponsor
- Myricx Pharma Limited
Melanoma (Skin)
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00538005
- Testing
- bevacizumab, oxaliplatin, sorafenib tosylate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Melanoma
Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Circulating tumor cells (CTC) are the subject of increasing interest in clinical oncology as a prognostic factor and predictor of therapeutic response.
- Trial name
- NCT01573494
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Advanced Solid Tumor, Advanced Breast Cancer
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
- Trial name
- NCT06120283
- Testing
- BGB-43395, Fulvestrant, Letrozole
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 433 people
- Sponsor
- BeOne Medicines
Solid Tumor
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
- Trial name
- NCT04111445
- Testing
- ADG116
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Adagene Inc
Non-small Cell Lung Cancer
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic…
- Trial name
- KEYNOTE B36 (NCT04892472)
- Testing
- NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
- Where
- 24 sites in United States
- Volunteers
- 15 people
- Sponsor
- NovoCure GmbH
Tumor, Ovarian Cancer
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced platinum-resistant ovarian cancer.
- Trial name
- NCT00806156
- Testing
- NKTR-102 q14d, NKTR-102 q21d
- Where
- 20 sites in United States, Belgium and 1 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Metastatic Breast Cancer
Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer
Patients with locally advanced or metastatic breast cancer and with measurable primary breast tumor will be treated with 70mg docetaxel combined with ketoconazole.
- Trial name
- NCT00212095
- Testing
- docetaxel and ketoconazole
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
NSCLC, Advanced Solid Tumor
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
This is an open-label, dose-escalation and cohort expansion study to evaluate the safety and preliminary efficacy of YSCH-01 in subjects with pulmonary metastasis of advanced solid tumors and advanced non-small cell lung cancer…
- Trial name
- NCT07793500
- Testing
- YSCH-01
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Adenocarcinoma, Metastatic Breast Carcinoma
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma…
- Conditions
- Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT03432741
- Testing
- Belinostat, Carfilzomib, Copanlisib Hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Malignant Tumor of Pancreas Metastatic to Liver
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
This study is a randomized open-label phase 2b study of the efficacy and safety of regional infusion therapy with Anti-CEA CAR-T cells using the hepatic immunotherapy for metastases (HITM) method and the Trisalus pressure…
- Trial name
- NCT04037241
- Testing
- Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA
- Sponsor
- Sorrento Therapeutics, Inc.
Renal Cell Carcinoma
Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA
The feasibility and dose-limiting toxicity of administering escalating doses of dendritic cells transfected with autologous renal cell carcinoma RNA DC(DCRCC-RNA) will be defined.
- Trial name
- NCT00006431
- Testing
- DC RCC-RNA
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.